OPKO Health Retain Recommendation Supported by Rayaldee Stability and Pipeline Progress

Earnings

โดย Zacks Investment Research·Read original

Summary · why it matters

Zacks Investment Research recommends retaining OPKO Health shares, citing Rayaldee's steady performance and advancing pipeline programs. Rayaldee generated $6.3 million in first-quarter 2026 revenues, while the company's ModeX platform is progressing multiple early-stage candidates including MDX2001, MDX2003, MDX2004, and the BARDA-funded MDX2301. OPKO also expanded its partnership with Nicoya Therapeutics, gaining a 15% equity stake and preserving up to $115 million in milestones for Rayaldee commercialization in Greater China. However, the firm notes risks from continued operating losses, clinical and regulatory uncertainty, and overdependence on Rayaldee. The Zacks Consensus Estimate for 2026 loss per share remains stable at 29 cents, with second-quarter 2026 revenue estimated at $131.1 million.

Opko Health Inc ▲